DON BRADY, MD

Transitional care management services for problem of at least moderate complexity

Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use

Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit

Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit

Sarscv2 vac 30mcg trs-suc im

Destruction of skin growth, 1-14 growths

Established patient office or other outpatient visit, 30-39 minutes

Pneumococcal vaccine, 23-valent

Destruction of precancer skin growth, 1 growth

Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza

Established patient office or other outpatient visit, 20-29 minutes

Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and

Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a

Admn sarscov2 vacc 1 dose

Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report

Removal of impacted ear wax by washing

Administration of influenza virus vaccine

Administration of vaccine

Administration of pneumococcal vaccine

Destruction of precancer skin growth, 2-14 growths

Automated urinalysis test